{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:19:54Z","timestamp":1783189194043,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303922"],"award-info":[{"award-number":["82303922"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472655"],"award-info":[{"award-number":["82472655"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373210"],"award-info":[{"award-number":["82373210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xcrm.2026.102747","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:10:53Z","timestamp":1776697853000},"page":"102747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Su","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Wen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Xuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Jie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-0205","authenticated-orcid":false,"given":"Li-Ru","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102747_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00262-023-03621-1","article-title":"Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data","volume":"73","author":"Yanagisawa","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102747_bib2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102747_bib3","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102747_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib6","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Bhayani SB, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Ellis R et al. (2019) Kidney cancer, version 3. NCCN."},{"key":"10.1016\/j.xcrm.2026.102747_bib7","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2026.102747_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic Ablative Radiation for Systemic Therapy-na\u00efve Oligometastatic Kidney Cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102747_bib11","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41467-022-29577-x","article-title":"A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population","volume":"13","author":"Qu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102747_bib12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41467-020-14601-9","article-title":"Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102747_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102747_bib14","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/ncomms6135","article-title":"Variation in genomic landscape of clear cell renal cell carcinoma across Europe","volume":"5","author":"Scelo","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102747_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000535","article-title":"Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study","volume":"4","author":"Dengina","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.xcrm.2026.102747_bib16","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2013.54.6911","article-title":"Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma","volume":"32","author":"Motzer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11523-019-00653-5","article-title":"Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data","volume":"14","author":"Moran","year":"2019","journal-title":"Target. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib18","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102747_bib22","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.euo.2025.03.009","article-title":"Predictive Factors for Oligometastatic Renal Cell Carcinoma Treated with Stereotactic Radiation: A Retrospective Study","volume":"8","author":"Yen","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","article-title":"Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?","volume":"80","author":"M\u00e9jean","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2026.102747_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clgc.2022.03.013","article-title":"Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry","volume":"20","author":"Meagher","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.xcrm.2026.102747_bib25","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bju.15284","article-title":"Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma","volume":"127","author":"Kroeze","year":"2021","journal-title":"BJU Int."},{"key":"10.1016\/j.xcrm.2026.102747_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2026.102747_bib29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2026.102747_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib31","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: a systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib32","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1007\/s00345-021-03742-1","article-title":"Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy","volume":"39","author":"Liu","year":"2021","journal-title":"World J. Urol."},{"key":"10.1016\/j.xcrm.2026.102747_bib33","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in metastatic breast cancer","volume":"22","author":"Hamaoka","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib34","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ijrobp.2016.03.027","article-title":"Postoperative Stereotactic Body Radiation Therapy (SBRT) for Spine Metastases: A Critical Review to Guide Practice","volume":"95","author":"Redmond","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.xcrm.2026.102747_bib35","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.prro.2021.10.004","article-title":"Stereotactic Radiosurgery for Postoperative Spine Malignancy: A Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines","volume":"12","author":"Faruqi","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib36","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/sj.bjc.6601703","article-title":"Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses","volume":"90","author":"Blancato","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102747_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/path.5551","article-title":"Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma","volume":"253","author":"De Rienzo","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.xcrm.2026.102747_bib38","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jval.2018.04.1370","article-title":"Time Trade-Off Value Set for EQ-5D-3L Based on a Nationally Representative Chinese Population Survey","volume":"21","author":"Zhuo","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.xcrm.2026.102747_bib39","article-title":"Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials","volume":"8","author":"Woodford","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib40","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102747_bib42","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.3747\/co.20.1596","article-title":"Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma","volume":"20","author":"Yildiz","year":"2013","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib43","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.21037\/jtd-20-3199","article-title":"Racial and socioeconomic disparities in the use of stereotactic body radiotherapy for treating non-small cell lung cancer: a narrative review","volume":"13","author":"Lin","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.xcrm.2026.102747_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ygyno.2021.01.041","article-title":"Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer","volume":"161","author":"Luo","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12939-021-01497-0","article-title":"The impact of sociodemographic factors on the utilization of radiation therapy in breast cancer patients in Estonia: a register-based study","volume":"20","author":"Shahrabi Farahani","year":"2021","journal-title":"Int. J. Equity Health"},{"key":"10.1016\/j.xcrm.2026.102747_bib46","doi-asserted-by":"crossref","first-page":"686.e1","DOI":"10.1016\/j.urolonc.2020.04.031","article-title":"Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors","volume":"38","author":"Haaker","year":"2020","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102747_bib47","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cncr.23776","article-title":"Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma","volume":"113","author":"Motzer","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2026.102747_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JOP.0922004","article-title":"Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa","volume":"5","author":"Cella","year":"2009","journal-title":"J. Oncol. Pract."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:07:02Z","timestamp":1783188422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666379126001643"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102747","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102747"}}